Regulatory Focus™ > News Articles > UK: Bayer's Blood Clot Drug Gets Draft OK From NICE

UK: Bayer's Blood Clot Drug Gets Draft OK From NICE

Posted 01 June 2012 | By Louise Zornoza

The UK's health technology assessment (HTA) body, the National Institute for Health and Clinical Excellent (NICE), has voted to recommended Bayer's drug Xarelto (rivaroxaban).

Xarelto is used to treat deep vein thrombosis, prevent recurrent deep vein thrombosis (VTE) and prevent pulmonary embolism in adults diagnosed with acute deep vein thrombosis (DVT).


The decision to recommend the drug is based on additional information that rivaroxaban was more clinically and cost effective than comparator drugs in patients for whom treatment up to 12 months is indicated. Some patients with ongoing risk factors for recurrence of VTE need ongoing treatment, possibly for many years or for life.


Read more:

NICE has recommended rivaroxaban

More Breaking News from RegLink


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe